Click here to view press releases from other months.
Subscribers click here to go straight to the cannabinoids and obesity review.
OMR has recently discovered that a new drug which antagonizes cannabinoid receptors is now in phase 2 human testing for weight loss , which means this drug will be on the market in less than five years if all goes well. In this upcoming article we provide an overview of the role of cannabinoid receptors in body weight, the results of animal studies on the compound, and the mechanisms by which it produces weight loss in humans. Dietary fat and leptin. Researchers hypothesize that dietary fat may be a cause of leptin resistance in humans, but to date, data supporting or disputing this theory is lacking. This month OMR summarizes recent research on dietary fat and leptin resistance, and discusses proposed mechanisms by which leptin resistance may occur.